Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Akira DoiHayato HikitaYugo KaiYuki TahataYoshinobu SaitoTasuku NakaboriRyoko YamadaTakahiro KodamaRyotaro SakamoriAsako MurayamaSayuri NittaYasuhiro AsahinaHiroshi SuemizuTomohide TatsumiTakanobu KatoTetsuo TakeharaPublished in: Journal of gastroenterology (2019)
Therapies combining at least two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents may be effective for HCV-infected patients with NS5A-P32del.